TCR-T cell therapy for KRAS-mutated advanced cancers
Treatments studied
Part of Cancer clinical trials.
This trial tests a new cell therapy (TCR-T) designed to target KRAS mutations in advanced cancers. It is for people whose standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 70 years old.
- You must have advanced solid tumors (like colorectal, non-small cell lung, or other cancers) that have not responded to standard treatments or you can't take them.
- Your tumor or blood must have a KRAS-G12V or G12D mutation and you must have specific tissue types (HLA-A*11:01 or HLA-C*01:02).
- You must have at least one tumor that can be measured on scans.
- You must be in fairly good health with adequate organ function (like blood counts, liver, kidney, heart).
- You cannot have other active cancers, serious autoimmune diseases, uncontrolled infections, or certain heart/lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (called RE002 T cells) for people with advanced solid tumors that have a specific KRAS G12V mutation and a certain HLA type. The therapy is designed to target and attack cancer cells that carry this mutation.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
This trial tests a new cell therapy called RE001 for people with advanced solid tumors that have a specific genetic change (KRAS G12V mutation). It uses your own immune cells modified to target cancer cells.
This study tests a new type of cell therapy called MSK-TCR5, designed to fight solid cancers (like pancreatic, lung, or colon cancer) that have a specific RAS G12D mutation. The therapy uses your own immune cells trained to recognize and attack cancer cells with this mutation.
This trial tests a personalized immune cell treatment made for people with advanced solid cancers that have not responded to standard care. It’s designed for tumors carrying a specific KRAS mutation (G12V or G12D) and for people whose immune “HLA type” matches the therapy.
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
Hear when a new KRAS G12V trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.